Advertisement

Journal of Endocrinological Investigation

, Volume 17, Issue 1, pp 1–5 | Cite as

Effects of ritanserin, a novel serotonin-s2 receptor antagonist, on the secretion of pituitary hormones in normal humans

  • Danilo Tepavčević
  • Z. Giljević
  • M. Korşić
  • S. Halimi
  • E. Suchanek
  • T. Jelić
  • I. Aganović
  • B. Kožić
  • V. Plavşić
Article

Abstract

The availability of a new potent and selective serotonin-S2 antagonist, ritanserin (RIT), encouraged us to further investigate the effect of serotonin on the basal secretion of anterior pituitary hormones in normal humans. Administered in a single 30-mg dose to group 1 consisting of 10 normal women, RIT failed to affect the baseline LH, FSH, GH or TSH levels. In group 2 consisting of 20 normal subjects (ten males and ten females), the same dose of RIT decreased in parallel both ACTH and Cortisol levels but only at 180 min. Group 3 consisting of 8 normal men was studied on three separate occasions seven days apart: each subject received graded doses of 10 mg, 20 mg and 30 mg RIT. The mean baseline PRL concentration at 180 min as well as the net integrated area under the hormone curve (nAUC) decreased only after the highest dose, while the baseline Cortisol concentrations at 180 min as well as the corresponding nAUC values displayed a clear dose-dependent response. The findings indicated the serotonin-S2 receptors to be only partially involved in the basal secretion of ACTH in normal humans.

Key-words

Ritaserin serotonin anterior pituitary hormones normal humans 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Delitala G., Masala A., Alagna S., Devilla L. Effect of cyproheptadine on the spontaneous diurnal variations of plasma ACTH-cortisol and ACTHGH secretion induced by L-DOPA. Biomed. (Express) 23: 406, 1975.Google Scholar
  2. 2.
    Cavagnini F., Raggi U., Micossi P., Di Landro A., Invitti C. Effect of an antiserotoninergic drug, metergoline, on the ACTH and Cortisol response to insulin hypoglycemia and lysine-vasopressin in man. J. Clin. Endocrinol. Metab. 43: 306, 1976.PubMedCrossRefGoogle Scholar
  3. 3.
    Lewis D.A., Sherman B.M. Serotoninergic stimulation of adrenocorticotropin secretion in man. J. Clin. Endocrinol. Metab. 58: 458, 1984.PubMedCrossRefGoogle Scholar
  4. 4.
    Plonk J.W., Bivens C.H., Feldman J.M. Inhibition of hypoglycemia-induced Cortisol secretion by the serotonin antagonist cyproheptadine. J. Clin. Endocrinol. Metab. 38: 836, 1974.PubMedCrossRefGoogle Scholar
  5. 5.
    Kletzky O.A., Marrs R.P., Nicoloff J.T. Effects of cyproheptadine on insulin-induced hypoglycemia secretion of PRL, GH and Cortisol. Clin. Endocrinol. (Oxf.) 73: 231, 1980.CrossRefGoogle Scholar
  6. 6.
    Bivens C.H., Lebovitz H.E., Feldman J.M. Inhibition of hypoglycemia-induced growth hormone secretion by serotonin antagonists cyproheptadine and methysergide. N. Engl. J. Med. 289: 236, 1973.PubMedCrossRefGoogle Scholar
  7. 7.
    Ferrari C, Paracchi A., Rondena M., Beck-Peccoz P., Faglia G. Effect of two serotonin antagonists on prolactin and thyrotrophin secretion in man. Clin. Endocrinol. (Oxf.) 5: 575, 1976.CrossRefGoogle Scholar
  8. 8.
    Egge A.C., Rogol A.D., Varma M.M., Blizzard R.M. Effect of cyproheptadine on TRH-stimulated prolactin and TSH release in man. J. Clin. Endocrinol. Metab. 44: 210, 1977.PubMedCrossRefGoogle Scholar
  9. 9.
    Golstein J., Vanhaelst L, Bruno O.D., L’Hermite M. Effect of cyproheptadine on thyrotropin and prolactin secretion in normal man. Acta Endocr. (Copenh) 92: 205, 1979.Google Scholar
  10. 10.
    Peroutka S.J., Snyder S.H. Multiple serotonin receptors: differential binding of 5-hydroxytryptamine (3H) lysergic acid diethylamide and (3H) spiroperidol. Mol. Pharmacol, 16: 687, 1979.PubMedGoogle Scholar
  11. 11.
    Leysen J.E., Awouters F., Kennis L, Laduron P.M., Vandenber J., Janssen P.A.J. Receptor binding profile of R-41-468, a novel antagonist at 5-HT2 receptors. Life Sci. 23: 1015, 1981.CrossRefGoogle Scholar
  12. 12.
    Leysen J.E., Gommeren W., Van Gompel P., Wynants J., Janssen P.F., Laduron P.M. Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist. Mol. Pharmacol. 27: 600, 1985.PubMedGoogle Scholar
  13. 13.
    Zoccali C., Zabludowski J.R., Isles C.G., Murray G.D., Inglis G.C., Robertson J.I.S., Fraser R., Ball S.G. The effect of a 5-HT antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympatho-adrenal function in normal man. Br. J. Clin. Pharmacol. 16: 306, 1983.CrossRefGoogle Scholar
  14. 14.
    Gordin A., Mustajoki P., Pelkonen R. Ketanserin without effects on basal anterior pituitary hormone secretion in healthy subjects. J. Endocrinol. Invest. 8: 73, 1985.PubMedCrossRefGoogle Scholar
  15. 15.
    Rocco A., De Giorgio G., Buongiorno T., Proietti A., Lucchetti G., Falaschi P. Prolactin response to R41468, a new specific 5HT-2 antagonist. Neuroendocrinol. Lett. 5: 47, 1983.Google Scholar
  16. 16.
    O’Malley B.P., Jennings P.E., Cook N., Barnett D.B., Rosenthal F.D. The role of serotonin (5-HT) in the control of TSH and prolactin release in euthyroid subjects as assessed by the administration of ketanserin (5-HT2 antagonist) and zimelidine (5-HT re-uptake inhibitor). Psychoneuroendocrinology 9: 13, 1984.PubMedCrossRefGoogle Scholar
  17. 17.
    Falaschi P., Rosa M., Rocco A., D’Urso R., Proietti A., Melis G.B. Effect of Ritanserin, specific 5HT-2 antagonist, on PRL secretion in normal subjects and in different hyperprolactinaemic conditions. Clin. Endocrinol. (Oxf.) 34: 449, 1991.CrossRefGoogle Scholar
  18. 18.
    Delitala G., Masala A., Alagna S., Devilla L., Rovasio P.P. Inhibition of prolactin release by metergoline administration in man. Biomed. (Express) 27: 31, 1977.Google Scholar
  19. 19.
    Krulich L, McCann S.M., Mayfield M.A. On the mode of the prolactin release-inhibiting action of the serotonin receptor blockers metergoline, methysergide and cyproheptadine. Endocrinology 708: 1115, 1981.CrossRefGoogle Scholar
  20. 20.
    Lesch K.P., Söhnle K., Poten B., Schoellnhammer G., Rupprecht R., Schulte H.M. Corticotropin and Cortisol secretion after central 5-hydroxytryptamine-1A (5-HT1A receptor activation: effects of 5-HT receptor and beta-adrenoceptor antagonist. J. Clin. Endocrinol. Metab. 70: 670, 1990.PubMedCrossRefGoogle Scholar
  21. 21.
    Krieger D.T., Rizzo F. Serotonin mediation of circadian periodicity of plasma 17-hydroxycorticosteroids. Am. J. Physiol. 217: 1703, 1969.PubMedGoogle Scholar
  22. 22.
    Reghunandanan V., Reghunandanan R., Marya R.K. Vasopressin: its possible role in circadian time keeping. Chronobiologia 18: 39, 1991.PubMedGoogle Scholar
  23. 23.
    Prescott R.W., Kendall-Taylor P., Weightman D.R., Watson M.J., Ratcliffe W.A. The effect of ketanserin, a specific serotonin antagonist on the PRL, GH, ACTH and Cortisol responses to hypoglycaemia in normal subjects. Clin. Endocrinol. (Oxf.) 20: 137, 1984.CrossRefGoogle Scholar
  24. 24.
    Facchinetti F., Martignoni E., Nappi G., Marini S., Petraglia F., Sandrini G., Genazzani A.R. Ritanserin, a serotonin-S2 receptor antagonist, does not prevent 5-hydroxytryptophan-induced beta-EP, beta LPH and Cortisol secretion. Hormone Res. 27: 42, 1987.PubMedCrossRefGoogle Scholar
  25. 25.
    Lee M.A., Nash J.F., Barnes M., Meitzer H.Y. Inhibitory effect of ritanserin on the 5-hydroxytryptophan-mediated Cortisol, ACTH and prolactin secretion in humans. Psychopharmacology (Berl.) 103: 253, 1991.CrossRefGoogle Scholar
  26. 26.
    Uretsky N.J., Iversen L.L. Effects of 6-hydroxy-dopamine on catecholamine containing neurons in the rat brain. J. Neurochem. 17: 269, 1970.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1994

Authors and Affiliations

  • Danilo Tepavčević
    • 1
  • Z. Giljević
    • 1
  • M. Korşić
    • 1
  • S. Halimi
    • 1
  • E. Suchanek
    • 1
  • T. Jelić
    • 1
  • I. Aganović
    • 1
  • B. Kožić
    • 1
  • V. Plavşić
    • 1
  1. 1.Division of Endocrinology, Department of Internal MedicineZagreb University School of Medicine, Zagreb Clinical CenterZagrebCroatia

Personalised recommendations